Concepedia

Menghui Chen

MC

Statistics

Publications

8

Citations

983

H-Index

8

Active since

2015

Affiliations

First Hospital of Shijiazhuang(Current)

Merck & Co., Inc., Rahway, NJ, USA (United States)

Hebei Medical University

Third Hospital of Hebei Medical University

Erasmus MC Cancer Institute

Menghui Chen is an author at First Hospital of Shijiazhuang specializing in medicine, pharmacotherapy, and rib fixation.

Publications per year

2015–2023

8

Publications

8

Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial

Catherine Thiéblemont, Tycel Phillips, Hervé Ghesquières et al. · Journal of Clinical Oncology · 2022 · 523 citations · Full text

, , +17

Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study

Jonathan Strosberg, Nobumasa Mizuno, Toshihiko Doi et al. · Clinical Cancer Research · 2020 · 221 citations · Full text

, , +17

A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus

Ira Gantz, Menghui Chen, Shailaja Suryawanshi et al. · Cardiovascular Diabetology · 2017 · 109 citations · Full text

, , +14

Safety and Efficacy of Omarigliptin (MK-3102), a Novel Once-Weekly DPP-4 Inhibitor for the Treatment of Patients With Type 2 Diabetes

Wayne Huey‐Herng Sheu, Ira Gantz, Menghui Chen et al. · Diabetes Care · 2015 · 64 citations · Full text

, , +17

Bioinformatics Analysis Reveals the Altered Gene Expression of Patients with Postmenopausal Osteoporosis Using Liuweidihuang Pills Treatment

Rui Gong, Shan Ren, Menghui Chen et al. · BioMed Research International · 2019 · 22 citations · Full text

, , +17

1–5 of 8